Ewing Sarcoma of the Sinonasal Tract: A Scoping Review
The Laryngoscope · 2025
DOI: 10.1002/lary.31925 ↗Kurz gefasst
Scoping Review in der Zeitschrift The Laryngoscope, 2025. Verfasst von Ariana L Shaari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A. Hauptthemen laut MEDLINE: Paranasal Sinus Neoplasms, Sarcoma, Ewing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 102 Literaturangaben.
Abstract (Originalsprache)
Objective
Ewing sarcoma (ES) is a rare aggressive malignancy that can present in the sinonasal region. The objective of this study is to investigate the demographics, presentation, management, and outcomes of patients with sinonasal ES. Data Sources PubMed, Web of Science, SCOPUS, CINAHL, and Cochrane Library. Review Methods A scoping review of cases of sinonasal ES was performed. Inclusion criteria consisted of case reports, series, or retrospective reviews.
Results
785 total articles were retrieved. 72 articles met inclusion criteria and were included in the final review for a total of 93 cases. 48 (53%) patients were male. Mean age at diagnosis was 26.4 years old (range 1–89). Nasal obstruction ( N = 55, 59%), epistaxis ( N = 35, 38%), and impaired vision ( N = 29, 29%) were the most common symptoms. On examination, 38 (41%) patients had a nasal cavity mass. Most tumors ( N = 33, 35%) were located in the maxillary sinus. 44 (47%) were left sided and 4 (4%) were bilateral. The most utilized treatment modalities were surgical resection with adjuvant chemoradiotherapy ( N = 27, 29%), chemoradiotherapy alone ( N = 24, 26%), and surgical resection with adjuvant chemotherapy ( N = 14, 15%). 56 patients had no evidence of disease (60%), 14 patients died with disease (15%), and 9 patients were alive with disease (10%) at the time of follow‐up.
Conclusions
To our knowledge, we report the first scoping review of sinonasal ES. Patients generally present with non‐specific sinonasal symptoms. Surgery with adjuvant chemoradiation is the most common treatment modality for these patients. Level of Evidence NA Laryngoscope , 135:1571–1580, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
- Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
- Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
- Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
- Department of Otolaryngology and Facial Plastic Surgery, Saint Barnabas Medical Center-RWJBarnabas Health, Livingston, New Jersey, U.S.A.
- Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, Bronx, New York, U.S.A.
ORCID-Profile: Ariana L Shaari, Rebecca Ho, Aman M Patel, Christina H Fang
Zitieren
APA
Shaari, A. L., Ho, R., Patel, A. M., Haimowitz, S., Eloy, J. A., & Fang, C. H. (2025). Ewing Sarcoma of the Sinonasal Tract: A Scoping Review. The Laryngoscope. https://doi.org/10.1002/lary.31925
Vancouver
Shaari AL, Ho R, Patel AM, Haimowitz S, Eloy JA, Fang CH. Ewing Sarcoma of the Sinonasal Tract: A Scoping Review. The Laryngoscope. 2025. doi:10.1002/lary.31925
BibTeX
@article{Shaari2025,
author = {Shaari, Ariana L and Ho, Rebecca and Patel, Aman M and Haimowitz, Sean and Eloy, Jean Anderson and Fang, Christina H},
title = {Ewing Sarcoma of the Sinonasal Tract: A Scoping Review},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.31925}
}
EUVIMED